Related Experiment Video
Updated: Nov 5, 2025

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
Doxorubicin-Dexrazoxane from Day 1 for Soft-tissue Sarcomas: The Road to Cardioprotection
Robert S Benjamin1, Giorgio Minotti2
1Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. rbenjami@mdanderson.org g.minotti@unicampus.it.
Abstract:
Doxorubicin cardiac toxicity is widely misunderstood, largely preventable, and starts with the first dose. This article reviews the history of doxorubicin cardiac toxicity and strategies for minimizing it. Dexrazoxane cardioprotection can safely be initiated on day 1 without compromising antitumor activity, allowing doxorubicin administration beyond the reported maximum lifetime dose.See related articles by Van Tine et al., p. 3854 and Jones et al., p. 3861.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
Cardiomyopathy II: Dilated Cardiomyopathy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

